{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"219","value":"460"},{"groupId":"OG001","spread":"115","value":"428"},{"groupId":"OG002","spread":"281","value":"451"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Tersirolimus Cmax (ng/mL) for cycle 1 is presented in the outcome measure table below for the 3 dose levels\n\nblood samples (5ml) was collected in EDTA containing tubes on days 1 and 2 of cycle 1\n\nCollection time points: prior to dosing of both drugs, at end of temsirolimus infusion and at 1,2,4,6, and 24 hr after erlotinib administration","dispersionType":"Standard Deviation","groups":[{"description":"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (15mg). Every 28 days until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 1 - 15mg"},{"description":"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (25mg). Every 28 days until disease progression or unacceptable toxicity.","id":"OG001","title":"Phase 1 - 25 mg"},{"description":"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (50mg). Every 28 days until disease progression or unacceptable toxicity.","id":"OG002","title":"Phase 1 - 50mg"}],"paramType":"MEAN","populationDescription":"per protocol","reportingStatus":"POSTED","timeFrame":"Days 1, 2 of cycle 1, prior to dosing of both drugs, at end of temsirolimus infusion and at 1,2,4,6, and 24 hr after erlotinib administration","title":"Pharmacokinetics (Phase I)","type":"PRIMARY","unitOfMeasure":"ng/mL"}